Insights On Enterprise Solutions
-
Meet An Optimized Suspension-Based Platform Technology
3/5/2024
Discover a ready-to-use, suspension-based platform technology for transient transfection of LVVs that eliminates the need to transition from small-scale adherent processes.
-
Response To FDA Black Box Warning
3/1/2024
The FDA has launched an investigation into the risk of T-cell malignancies following CAR-T cell immunotherapies. Review the key points of this announcement concerning the CGT research community.
-
Bubbling Innovation: Dynamic Trends Shaping The Future Of Microbial Fermentation
3/1/2024
Drug developers must understand the latest trends in microbial fermentation. By leveraging innovative methods and technologies, developers can unlock new opportunities and improve patient outcomes.
-
Accelerating Rare Disease Treatments From Concept To Cure
2/29/2024
Access a thorough investigation that delves into the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.
-
Analyzing The Process For Single-Use Prokaryotic Cell Cultivation
2/29/2024
Aseptic risk management plays a crucial role in bioproduct safety and efficacy. Discover a process for single-use production and automation control logic that ensures stable and efficient production.
-
Three Benefits Of Partnering With A CDMO For CGT Manufacturing
2/29/2024
By leveraging the capabilities of a CDMO, pharmaceutical companies can focus on their core competencies and accelerate the development and delivery of life-saving therapies to patients.
-
Abzena Capacity Update February 2024: Large Molecule
2/28/2024
Hear expert insight from Abzena’s CTO on how to de-risk and streamline the development of your biopharmaceutical in order to successfully meet your next regulatory or clinical milestone.
-
Ajinomoto Bio-Pharma Services Capacity Update February 2024: Small Molecule
2/28/2024
Explore the recent expansions of Ajinomoto BPS. Our experts delve into the advancements in our development and manufacturing capabilities for HPAPI, clinical development, and late-stage projects.
-
Nanoform Capacity Update February 2024: Small Molecule
2/28/2024
Discover Nanoform’s manufacturing capabilities, its CESS technology for nanoparticle generation, and the types of particles that can be generated without the need for solvents or excipients.
-
EirGenix Inc. Capacity Update February 2024: Large Molecule
2/28/2024
EirGenix has immediate availability of capacity up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial and that will increase to 350L and 1,000L by end of this year.